Internal medicine journal
-
Since the recognition of BRAF V600E mutations in the majority of cases of hairy cell leukaemia, Erdheim-Chester disease and Langerhans cell histiocytosis, the targeted oral kinase inhibitors dabrafenib and vemurafenib have been adapted for their treatment. Like other targeted agents, these drugs produce high response rates and predictable but unique side effects. Physician familiarity is essential for the effective use of these agents. We review the Australian experience of BRAF/MEK inhibitor therapy in these rare haematological cancers.
-
Internal medicine journal · May 2023
Review'Neurosyphilis in the Northern Territory of Australia: a clinical guideline'.
The Northern Territory (NT) of Australia is currently experiencing a syphilis epidemic. Neurosyphilis is commonly considered in the differential diagnosis for patients presenting with neurologic conditions such as dementia and stroke in the NT. ⋯ A clinical guideline and algorithm have been developed for the diagnosis and management of patients with neurosyphilis.
-
Internal medicine journal · May 2023
Non-beneficial resuscitation during in-hospital cardiac arrests in a metropolitan teaching hospital.
There is increasing recognition that a proportion of hospitalised patients receive non-beneficial resuscitation, with the potential to cause harm. ⋯ Over one in seven resuscitation attempts were non-beneficial. MET reviews and specialist ward rounds provide opportunities to improve the documentation and visibility of NFR status.